PREDICTION OF CLINICAL OUTCOME AND ANTIANGIOGENIC THERAPY FOR PEDIATRIC PATIENTS WITH NON-METASTATIC EWING’S SARCOMA

2017 ◽  
Vol 4 (2) ◽  
pp. 105-114
Author(s):  
L. Kisialeu ◽  
T. Savitskaia ◽  
O. Aleinikova
Keyword(s):  
Clinical Outcome ◽  
Pediatric Patients ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Antiangiogenic Therapy

Abstract 4640: High expression of the stem cell marker LGR5 is associated with a poor clinical outcome in patients with Ewing's sarcoma

2010 ◽  
Author(s):  
Christopher A. Scannell ◽  
Diana Abdueva ◽  
Lingyun Ji ◽  
Cornelia von Levetzow ◽  
Richard Sposto ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Outcome ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
High Expression ◽  
Stem Cell Marker ◽  
Cell Marker ◽  
Poor Clinical Outcome

Combination antiangiogenic therapy inhibits anti-VEGF tachyphylaxis and prolongs survival in a murine model of Ewing's sarcoma

2010 ◽  
Vol 211 (3) ◽  
pp. S73
Author(s):  
Amir S. Gendy ◽  
Aaron Lipskar ◽  
Richard D. Glick ◽  
Bettie M. Steinberg ◽  
Morris Edelman
Keyword(s):  
Murine Model ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Antiangiogenic Therapy ◽  
Anti Vegf

scholarly journals Role of radiation therapy in the multidisciplinary management of Ewing's Sarcoma of bone in pediatric patients: An effective treatment for local control

2011 ◽  
Vol 16 (3) ◽  
pp. 103-109 ◽  
Author(s):  
Jose Luis Lopez ◽  
Patricia Cabrera ◽  
Rafael Ordoñez ◽  
Catalina Marquez ◽  
Gema Lucia Ramirez ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Effective Treatment ◽  
Local Control ◽  
Pediatric Patients ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Multidisciplinary Management

scholarly journals Extraskeletal Ewing's Sarcoma Family of Tumors in Adults: Prognostic Factors and Clinical Outcome

2012 ◽  
Vol 42 (5) ◽  
pp. 420-426 ◽  
Author(s):  
D. Tural ◽  
N. Molinas Mandel ◽  
S. Dervisoglu ◽  
F. Oner Dincbas ◽  
S. Koca ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcome ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Extraskeletal Ewing’S Sarcoma

Non-Metastatic Ewing's Sarcoma Family of Tumors of Bone in Adolescents and Adults: Prognostic Factors and Clinical Outcome-Single Institution Results

2014 ◽  
Vol 100 (4) ◽  
pp. 452-458 ◽  
Author(s):  
Didem Colpan Öksüz ◽  
Deniz Tural ◽  
Fazilet Öner Dincbas ◽  
Sergülen Dervisoglu ◽  
Hande Turna ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Clinical Outcome ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Single Institution ◽  
Adolescents And Adults ◽  
Tumors Of Bone

Cyclophosphamide Plus Topotecan in Children With Recurrent or Refractory Solid Tumors: A Pediatric Oncology Group Phase II Study

2001 ◽  
Vol 19 (15) ◽  
pp. 3463-3469 ◽  
Author(s):  
Robert L. Saylors ◽  
Kimo C. Stine ◽  
Jim Sullivan ◽  
James L. Kepner ◽  
Donna A. Wall ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Stable Disease ◽  
Pediatric Patients ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Complete Response ◽  
Median Number ◽  
Pediatric Oncology Group ◽  
Hematopoietic Toxicity ◽  
Grade 3

PURPOSE: To determine the response rate of the combination of cyclophosphamide and topotecan in pediatric patients with recurrent or refractory malignant solid tumors. PATIENTS AND METHODS: A total of 91 pediatric patients, 83 of whom were fully assessable for response and toxicity, received cyclophosphamide (250 mg/m2/dose) followed by topotecan (0.75 mg/m2/dose), each given as a 30-minute infusion daily for 5 days. All patients received filgrastim (5 mcg/kg) daily until the absolute neutrophil count (ANC) was ≥ 1,500 μL after the time of the expected ANC nadir. RESULTS: A total of 307 treatment courses were given to the 83 fully assessable patients. Responses (complete response plus partial response) were seen in rhabdomyosarcoma (10 of 15 patients), Ewing’s sarcoma (six of 17 patients), and neuroblastoma (six of 13 patients). Partial responses were seen in two of 18 patients with osteosarcoma and in one patient with a Sertoli-Leydig cell tumor. Twenty-three patients had either minor responses (n = 6) or stable disease (n = 17); the median number of courses administered to patients with partial or complete response was six (range, two to 13 courses), and the median administered to those with stable disease was three (range, one to 11 courses). The toxicity of the combination was limited principally to the hematopoietic system. Of 307 courses, 163 (53%) were associated with grade 3 or 4 neutropenia, 84 (27%) with grade 3 or 4 anemia, and 136 (44%) with grade 3 or 4 thrombocytopenia. Despite the severe myelosuppression, only 34 (11%) of 307 courses were associated with grade 3 or 4 infection. Nonhematopoietic toxicity of grades ≥ 3 was rare and consisted of nausea and vomiting (two courses), perirectal mucositis (one course), transaminase elevation (one course), and hematuria (two courses). CONCLUSION: The combination of cyclophosphamide and topotecan is active in rhabdomyosarcoma, neuroblastoma, and Ewing’s sarcoma. Stabilization of disease was seen in osteosarcoma, although objective responses were rare in this disease. The therapy can be given with acceptable hematopoietic toxicity with the use of filgrastim support.

Sign in / Sign up

Export Citation Format

Share Document